JP2017501143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501143A5 JP2017501143A5 JP2016536812A JP2016536812A JP2017501143A5 JP 2017501143 A5 JP2017501143 A5 JP 2017501143A5 JP 2016536812 A JP2016536812 A JP 2016536812A JP 2016536812 A JP2016536812 A JP 2016536812A JP 2017501143 A5 JP2017501143 A5 JP 2017501143A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- region
- sequence
- tslpr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 5
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000005754 cellular signaling Effects 0.000 claims 4
- 230000003834 intracellular effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021086485A JP7100177B2 (ja) | 2013-12-06 | 2021-05-21 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361912948P | 2013-12-06 | 2013-12-06 | |
| US61/912,948 | 2013-12-06 | ||
| US201461991697P | 2014-05-12 | 2014-05-12 | |
| US61/991,697 | 2014-05-12 | ||
| PCT/US2014/063096 WO2015084513A1 (en) | 2013-12-06 | 2014-10-30 | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086485A Division JP7100177B2 (ja) | 2013-12-06 | 2021-05-21 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501143A JP2017501143A (ja) | 2017-01-12 |
| JP2017501143A5 true JP2017501143A5 (enExample) | 2017-11-30 |
| JP6943568B2 JP6943568B2 (ja) | 2021-10-06 |
Family
ID=51946020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536812A Active JP6943568B2 (ja) | 2013-12-06 | 2014-10-30 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
| JP2021086485A Active JP7100177B2 (ja) | 2013-12-06 | 2021-05-21 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021086485A Active JP7100177B2 (ja) | 2013-12-06 | 2021-05-21 | 胸腺間質性リンパ球新生因子受容体特異的キメラ抗原受容体及びそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10676528B2 (enExample) |
| EP (1) | EP3077416B1 (enExample) |
| JP (2) | JP6943568B2 (enExample) |
| CN (1) | CN105899531B (enExample) |
| CA (1) | CA2932424C (enExample) |
| RU (1) | RU2701346C1 (enExample) |
| SG (1) | SG11201604565WA (enExample) |
| WO (1) | WO2015084513A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11299546B2 (en) | 2016-05-27 | 2022-04-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | FLT3-specific chimeric antigen receptors and methods using same |
| US11453712B2 (en) | 2016-09-02 | 2022-09-27 | Lentigen Technology Inc. | Compositions and methods for treating cancer with DuoCARs |
| EP3606548A4 (en) * | 2017-04-04 | 2021-03-24 | Loma Linda University | BIOLOGICAL PREPARATION FOR TREATMENT OF CANCER |
| EP3697426B1 (en) * | 2017-10-16 | 2023-07-26 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd22 immunotherapy |
| CN110526985A (zh) * | 2018-05-25 | 2019-12-03 | 深圳宾德生物技术有限公司 | 一种靶向egfr的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN111632135A (zh) * | 2020-05-09 | 2020-09-08 | 深圳宾德生物技术有限公司 | 靶向nkg2d的嵌合抗原受体t细胞在治疗前列腺癌中的应用、治疗前列腺癌的药物 |
| JP2023530997A (ja) * | 2020-06-19 | 2023-07-20 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体 |
| CA3171101A1 (en) * | 2020-06-22 | 2021-12-30 | Dina SCHNEIDER | Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy |
| EP4259105A4 (en) * | 2020-10-13 | 2025-08-06 | Univ Pennsylvania | IN VIVO TARGETING OF CD4+ T CELLS FOR MRNA-BASED THERAPIES |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| US20240360233A1 (en) * | 2021-08-27 | 2024-10-31 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3832253A (en) | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4667014A (en) | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| CA1200416A (en) | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IN165717B (enExample) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| JPH04167172A (ja) | 1990-10-31 | 1992-06-15 | Nec Corp | ベクトルプロセッサ |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| MXPA02012747A (es) | 2000-06-28 | 2003-09-25 | Amgen Inc | Moleculas del receptor de linfopoietina estromica timica y sus usos. |
| GB0603683D0 (en) * | 2006-02-23 | 2006-04-05 | Novartis Ag | Organic compounds |
| US20100105136A1 (en) | 2006-10-09 | 2010-04-29 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| AR064333A1 (es) | 2006-12-14 | 2009-04-01 | Schering Corp | Anticuerpo anti-tslp de diseno |
| JP2011511638A (ja) * | 2008-02-07 | 2011-04-14 | シェーリング コーポレイション | 抗ｔｓｌｐｒ抗体の設計製作 |
| WO2011014871A1 (en) * | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013103614A1 (en) | 2011-12-30 | 2013-07-11 | Stc.Unm | Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all) |
| WO2013105089A2 (en) | 2012-01-09 | 2013-07-18 | Yada Research And Development Co. Ltd. | Anti-inflammatory peptides and use thereof |
| AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US9597357B2 (en) * | 2012-10-10 | 2017-03-21 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| MX374929B (es) * | 2013-02-20 | 2025-03-06 | Novartis Ag | RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO. |
| PL3071222T3 (pl) * | 2013-11-21 | 2021-04-19 | Ucl Business Ltd | Komórka |
| WO2015118124A1 (en) * | 2014-02-06 | 2015-08-13 | Vib Vzw | Thymic stromal lymphopoietin receptor antagonist |
| US11453712B2 (en) * | 2016-09-02 | 2022-09-27 | Lentigen Technology Inc. | Compositions and methods for treating cancer with DuoCARs |
-
2014
- 2014-10-30 EP EP14802259.3A patent/EP3077416B1/en active Active
- 2014-10-30 RU RU2016124670A patent/RU2701346C1/ru active
- 2014-10-30 JP JP2016536812A patent/JP6943568B2/ja active Active
- 2014-10-30 WO PCT/US2014/063096 patent/WO2015084513A1/en not_active Ceased
- 2014-10-30 US US15/101,583 patent/US10676528B2/en active Active
- 2014-10-30 CN CN201480072437.4A patent/CN105899531B/zh active Active
- 2014-10-30 SG SG11201604565WA patent/SG11201604565WA/en unknown
- 2014-10-30 CA CA2932424A patent/CA2932424C/en active Active
-
2020
- 2020-04-28 US US16/860,216 patent/US11834509B2/en active Active
-
2021
- 2021-05-21 JP JP2021086485A patent/JP7100177B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501143A5 (enExample) | ||
| Yamauchi et al. | T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors | |
| Klebanoff et al. | T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome | |
| Mehta et al. | An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA | |
| Burrack et al. | Combination PD-1 and PD-L1 blockade promotes durable neoantigen-specific T cell-mediated immunity in pancreatic ductal adenocarcinoma | |
| Rich et al. | Survey of the year 2006 commercial optical biosensor literature | |
| RU2016124670A (ru) | Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения | |
| Van Blarcom et al. | Precise and efficient antibody epitope determination through library design, yeast display and next-generation sequencing | |
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| Cummings et al. | The role of next‐generation sequencing in enabling personalized oncology therapy | |
| JP2016536330A5 (enExample) | ||
| JP6239503B2 (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| JP2008535477A5 (enExample) | ||
| JP2016516735A5 (enExample) | ||
| WO2017192924A1 (en) | Cell-based neoantigen vaccines and uses thereof | |
| JP2017531430A5 (enExample) | ||
| JP2020522261A5 (enExample) | ||
| JP2017508442A5 (enExample) | ||
| JP2015517982A5 (enExample) | ||
| KR20180054829A (ko) | 면역 레퍼토리 정상성 평가 방법 및 그 용도 | |
| WO2015084808A4 (en) | Identification of predictive biomarkers associated with wnt pathway inhibitors | |
| WO2018089910A2 (en) | Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells | |
| CN115087749A (zh) | 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 | |
| JP2017538412A5 (enExample) | ||
| US20240369565A1 (en) | Circulating Tumor Cell Enrichment Using Neoepitopes |